Medy-Tox Valuation Multiples

Medy-Tox Overview

About Medy-Tox

Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Founded

2000

HQ

Employees

N/A

Website

medytox.com

Sectors

BiopharmaceuticalsNutraceuticals & CosmeceuticalsBioTech

Financials (LTM)

Revenue: $170M

EBITDA: $18M

EV

$496M

Valuation Multiples

Multiples.vc

Start free trial

Medy-Tox Financials

Medy-Tox reported last 12-month revenue of $170M and EBITDA of $18M.

In the same LTM period, Medy-Tox generated $105M in gross profit, $18M in EBITDA, and $13M in net income.

Medy-Tox P&L

In the most recent fiscal year, Medy-Tox reported revenue of $167M and EBITDA of $18M.

Medy-Tox expects next 12-month revenue of XXX and NTM EBITDA of XXX

Medy-Tox Stock Performance

Medy-Tox has current market cap of $477M, and enterprise value of $496M.

Medy-Tox's stock price is $72.53.

Medy-Tox Valuation Multiples

Medy-Tox trades at 2.9x EV/Revenue multiple, and 26.8x EV/EBITDA.

Medy-Tox Financial Valuation Multiples

As of April 19, 2026, Medy-Tox has market cap of $477M and EV of $496M.

Equity research analysts estimate Medy-Tox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medy-Tox has a P/E ratio of 37.7x.

Medy-Tox Margins & Growth Rates

Medy-Tox's revenue in the last 12 month grew by 9%.

Medy-Tox's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medy-Tox's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Medy-Tox Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Nutraceuticals & Cosmeceuticals comps.

Medy-Tox M&A Activity

Medy-Tox acquired XXX companies to date.

Last acquisition by Medy-Tox was on XXXXXXXX, XXXXX. Medy-Tox acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Medy-Tox Investment Activity

Medy-Tox invested in XXX companies to date.

Medy-Tox made its latest investment on XXXXXXXX, XXXXX. Medy-Tox invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).